199166-39-7

Basic information

• Product Name: Boc-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl
• Synonyms: Boc-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl
• CAS NO: 199166-39-7
• Molecular Weight: 950.123
• Mol File: 199166-39-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Boc-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl(199166-39-7)
• EPA Substance Registry System: Boc-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl(199166-39-7)

Safety Data

• Hazardous Substances Data: 199166-39-7(Hazardous Substances Data)

Upstream product

• 73821-95-1 Boc-Asp(O-cyclohexyl)-OH 
• 13836-37-8 Boc-Arg(Tos)-OH 
• 69871-79-0 (S)-benzyl 3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)propanoate 
• 199166-37-5 N-(2-benzyloxy-1-benzyloxycarbonyl-ethyl)-3-(2-tert-butoxycarbonylamino-acetylamino)-succinamic acid cyclohexyl ester 
• 788804-09-1 (S)-3-(2-Amino-acetylamino)-N-((S)-2-benzyloxy-1-benzyloxycarbonyl-ethyl)-succinamic acid cyclohexyl ester 
• 105916-77-6 N^α-Boc-N^δ-tosyl-Arg-OBt 
• 171519-62-3 Boc-Asp(OcHex)-Ser(Bzl)-OBzl 
• 792169-28-9 (S)-3-Amino-N-((S)-2-benzyloxy-1-benzyloxycarbonyl-ethyl)-succinamic acid cyclohexyl ester 

Downstream Products

• 642097-78-7 1-(1',3'-dioxyl-4',4',5',5'-tetramethyldihydroimidazol-2'-yl)-phenyl-4-yloxylacetyl-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl 
• 774164-79-3 C₄₂H₅₅N₇O₁₀S 
• 91037-65-9 H-Arg-Gly-Asp-Ser-OH 

Relevant articles and documents

Dual-acting agents that possess free radical scavenging and antithrombotic activities: Design, synthesis, and evaluation of phenolic tetrahydro-β-carboline RGD peptide conjugates

A new approach to construct a single dual-acting agent is described. Compounds 6a-c are potent free radical scavengers as demonstrated by the EC50 values in PC12 cell survival assay in term of NO, H2O2, and {radical dot}OH scavenging activity. The Ach-induced vaso-relaxation assay further confirms the potent NO scavenging activity of compounds 6a-c. In addition, 6a-c are efficacious in a rat arterial thrombosis, and are active in ADP- or PAF-induced in vitro platelet aggregation assay, suggesting that compounds 6a-c also possess anti-thrombotic activities. Since both free radical and thrombogenesis are important risk factors in myocardial ischemic/reperfusion injuries, these dual-acting agents having both free radical scavenging and antithrombolic activities may potentially be beneficial toward their treatment.